- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03203551
Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.
June 29, 2017 updated by: Cláudia Helena Lovato da Silva, University of Sao Paulo
Clinical and Laboratorial Evaluation of the Effect of Sodium Hypochlorite, Chloramine T and Ricinus Communis Solutions in Candida Species Identified in the Biofilm of Total Prostheses and Palate of Total Edentulous Individuals.
This clinical study identified the Candida species from the palate and complete dentures of edentulous individuals with prostheses-related stomatitis (PRS) and evaluated the effect of disinfectant solutions for denture hygiene on Candida spp.
Sixty participants were randomly assigned in 04 parallel groups (n = 15); They were oriented to brush their prostheses and the palate 3 times a day and immerse them in saline solution (C-control), 0.25% Sodium hypochlorite (HS0.25%),
10% Ricinus communis (RC10%) or 0.5% Chloramine T (CT 0.5%) for 20 minutes.
Biofilm samples were collected from the prostheses and palate in the baseline, after 7 and 37 days of use of the solutions and seeded in CHROMagar Candida medium.
After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed.
To quantify biofilm with software ImageTool 3.0, the inner surface was disclosed (1% neutral red) and photographed at the end of each period.
The Candidiasis remission was assessed by scores before and after the use of solutions by palate's phographs.
Descriptive analyzes were used for the identification and incidence of Candida spp.
Kruskal-Wallis and Friedman tests, with stepwise step-down post-test for cell growth; ANOVA and Tukey for biofilm removal; Frequency of scores for evolution of inflammation.
Level of significance was 95%.
The most incident species were C. albicans, followed by C. tropicalis, C. glabrata and C. krusei.
HS 0.25% reduced the incidence of the three species on the prostheses and palate in the periods of 7 and 37 days; CT 0.5% promoted reduction of Candida spp.
only in dentures.
R. communis decreased the incidence of C. tropicalis in both collection sites.
For CFU counts, HS 0.25% and CT 0.5% caused significant reduction.
For biofilm removal, HS0.25% was the most effective (9.75 ± 12.6) and RC10% (15.92 ± 14.8) intermediate.
All groups decreased protheses-related stomatitis.
HS0.25% has potential for clinical use as total denture disinfectants.
RC10% and CT0.5% require further studies to be indicated as alternative solutions.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
108
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion criteria:
- providing consent prior to participation in the study;
- being at least 18 years of age;
- maxillary complete conventional denture in good state and 1 year of use;
- dentures with biofilm in a internal surface;
- moderate to severe signs of Candidiasis.
Exclusion criteria:
- presence oral mucosal lesions apart from Candidiasis;
- systemic or local conditions which predispose to Candida spp. infection;
- history of chemotherapy/ radiotherapy;
- having taken or used antibiotics, steroidal agents, or antifungal agents in the three months prior to the study;
- being scheduled to replace existing dentures with new ones during the period of the trial;
- dentures with adaptation or retention problems;
- already using palatal brushing or disinfectant solutions as a routine oral hygiene.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: C; Control; Saline solution
Disinfection protocol:
Periods of analysis (Baseline, 7 and 37 days):
|
The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Other Names:
|
|
Experimental: HS0.25%; 0.25% Sodium Hypochlorite
Disinfection protocol:
Periods of analysis (Baseline, 7 and 37 days):
|
The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Other Names:
|
|
Experimental: RC10%; 10% Ricinus communis
Disinfection protocol:
Periods of analysis (Baseline, 7 and 37 days):
|
The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Other Names:
|
|
Experimental: CT0.5%; 0.5% Chloramine T
Disinfection protocol:
Periods of analysis (Baseline, 7 and 37 days):
|
The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical evaluation of the Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals.
Time Frame: Baseline (without disinfection procedures)
|
Biofilm samples were collected from the prosthesis and palate in the baseline and seeded in CHROMagar Candida medium.
After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed.
The inner surface of the denture was disclosed (1% neutral red) and photographed at the end to quantify the biofilm with the software ImageTool 3.0.
The palate with Candidiasis was photographed and assessed by scores.
|
Baseline (without disinfection procedures)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical evaluation of the effect of Sodium hypochlorite, Chloramine T and Ricinus communis solutions after 7 days of use in Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals.
Time Frame: 7 days of disinfection
|
Biofilm samples were collected from the prostheses and palate after 7 days of use of the solutions and seeded in CHROMagar Candida medium.
After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed.
To quantify the denture biofilm with software ImageTool 3.0, the inner surface of the denture was disclosed (1% neutral red) and photographed at the end of 7 days.
The Candidiasis remission was photographed and assessed by scores after 7 days of use solutions.
|
7 days of disinfection
|
|
Clinical evaluation of the effect of Sodium hypochlorite, Chloramine T and Ricinus communis solutions after 37 days of use in Candida species identified in the biofilm of total prostheses and palate of total edentulous individuals.
Time Frame: 37 days of disinfection
|
Biofilm samples were collected from the prostheses and palate after 37 days of use of the solutions and seeded in CHROMagar Candida medium.
After incubation period, the presumptive identification, incidence verification and quantification of Candida species growth (CFU count) were performed.
To quantify the denture biofilm with software ImageTool 3.0, the inner surface of the denture was disclosed (1% neutral red) and photographed at the end of 37 days.
The Candidiasis remission was photographed and assessed by scores after 37 days of use solutions.
|
37 days of disinfection
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2014
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
July 1, 2016
Study Registration Dates
First Submitted
June 23, 2017
First Submitted That Met QC Criteria
June 27, 2017
First Posted (Actual)
June 29, 2017
Study Record Updates
Last Update Posted (Actual)
July 2, 2017
Last Update Submitted That Met QC Criteria
June 29, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FORP/USP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Candidiasis
-
Robert Krause, MDCompletedInvasive Candidiasis | Pulmonary CandidiasisAustria
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States, South Africa
-
Astellas Pharma IncCompletedCandidemia | Invasive Candidiasis | Esophageal Candidiasis | Oropharyngeal CandidiasisUnited States
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Children's Hospital...CompletedPediatric Invasive CandidiasisUnited States, Colombia, Canada, India, Saudi Arabia, Greece, Italy, Spain
-
Centre Hospitalier Universitaire DijonCompleted
-
University Hospital OstravaUniversity Hospital, MotolRecruiting
-
Yung Shin Pharm. Ind. Co., Ltd.Completed
-
Duke UniversityChildren's Hospital of PhiladelphiaCompletedInvasive CandidiasisUnited States, Saudi Arabia, Greece, Spain
-
Merck Sharp & Dohme LLCTerminated
-
Hasan Al-DorziKing Fahad Medical CityCompleted
Clinical Trials on Disinfection Protocol
-
Yuzuncu Yıl UniversityCompleted
-
Hôpital du ValaisUnknown
-
Cairo UniversityCompletedDental Pulp Necrosis | Dental Pulp Disease | Dental Pulp; DegenerationEgypt
-
Hospital Israelita Albert EinsteinHospital Moinhos de Vento; Hospital do Coracao; Hospital Sirio-Libanes; Hospital... and other collaboratorsCompleted
-
Örebro University, SwedenCompleted
-
Yuzuncu Yıl UniversityCompleted
-
The First Affiliated Hospital of Zhejiang Chinese...CompletedDaily Room Disinfection | After-each-case Room DisinfectionChina
-
University of California, BerkeleySwiss Tropical & Public Health Institute; Universidad de San SimonCompleted
-
Johns Hopkins UniversityCompletedHealthcare Associated Infection | Multidrug Resistant Organisms
-
Council for Scientific and Industrial Research,...Royal College of Surgeons, Ireland; European UnionCompletedDiarrhea | Dysentery (Bloody Diarrhea)South Africa